ArrowMark Colorado Holdings LLC Purchases Shares of 243,788 Stevanato Group S.p.A. (NYSE:STVN)

ArrowMark Colorado Holdings LLC acquired a new stake in shares of Stevanato Group S.p.A. (NYSE:STVN - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 243,788 shares of the company's stock, valued at approximately $5,312,000. ArrowMark Colorado Holdings LLC owned 0.08% of Stevanato Group at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Van Berkom & Associates Inc. purchased a new position in Stevanato Group in the 4th quarter worth about $39,000. Johnson Financial Group Inc. purchased a new stake in shares of Stevanato Group in the 4th quarter valued at approximately $41,000. Wells Fargo & Company MN grew its position in Stevanato Group by 680.3% during the 4th quarter. Wells Fargo & Company MN now owns 3,246 shares of the company's stock worth $71,000 after purchasing an additional 2,830 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in Stevanato Group by 1,457.6% during the 4th quarter. PNC Financial Services Group Inc. now owns 5,654 shares of the company's stock valued at $123,000 after purchasing an additional 5,291 shares during the period. Finally, Tower Research Capital LLC TRC boosted its position in shares of Stevanato Group by 202.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 7,413 shares of the company's stock worth $162,000 after buying an additional 4,965 shares during the period.

Stevanato Group Stock Up 5.3 %

NYSE:STVN traded up €1.19 ($1.34) during trading hours on Friday, reaching €23.67 ($26.60). The company's stock had a trading volume of 374,495 shares, compared to its average volume of 347,370. Stevanato Group S.p.A. has a one year low of €16.56 ($18.61) and a one year high of €24.90 ($27.98). The business's 50-day moving average is €21.03 and its 200-day moving average is €20.94. The company has a market cap of $7.17 billion, a price-to-earnings ratio of 50.36, a price-to-earnings-growth ratio of 7.18 and a beta of 0.51. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.81 and a quick ratio of 1.21.

Stevanato Group (NYSE:STVN - Get Free Report) last issued its quarterly earnings data on Thursday, March 6th. The company reported €0.20 ($0.22) earnings per share for the quarter, meeting analysts' consensus estimates of €0.20 ($0.22). The business had revenue of €352.68 million for the quarter, compared to the consensus estimate of €346.26 million. Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. Equities research analysts predict that Stevanato Group S.p.A. will post 0.5 EPS for the current year.

Stevanato Group Increases Dividend

The company also recently announced an annual dividend, which will be paid on Thursday, July 17th. Investors of record on Thursday, June 5th will be issued a $0.0613 dividend. This represents a yield of 0.3%. The ex-dividend date of this dividend is Thursday, June 5th. This is an increase from Stevanato Group's previous annual dividend of $0.05. Stevanato Group's dividend payout ratio (DPR) is 12.50%.

Analyst Ratings Changes

STVN has been the topic of several research analyst reports. UBS Group lowered their target price on Stevanato Group from $24.00 to $23.50 and set a "neutral" rating on the stock in a research note on Friday, March 7th. Stephens upgraded shares of Stevanato Group to a "strong-buy" rating in a research note on Monday, April 21st. Finally, William Blair restated an "outperform" rating on shares of Stevanato Group in a report on Friday, March 7th. Two analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of €25.70 ($28.88).

Stevanato Group Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.